Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 46 slides
46 pages · 3 arc beats · 2 loops
Immix Biopharma | Investor Presentation Deck | 46 slides
Immix Biopharma · 2023-08 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
1246810121416182022242628303234363840424446
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 14 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 3 slides 100% 3/3 slides 100% 3/3 slides · 17 hits — 0/3 slides
33.3% 1/3 slides 33.3% 1/3 slides 100% 3/3 slides 66.7% 2/3 slides Agitate (Make it worse) 4 slides 100% 4/4 slides 100% 4/4 slides · 16 hits — 0/4 slides
— 0/4 slides
25% 1/4 slides 100% 4/4 slides 100% 4/4 slides Solution (Provide relief) 7 slides 100% 7/7 slides 100% 7/7 slides · 38 hits — 0/7 slides
57.1% 4/7 slides · 5 hits 28.6% 2/7 slides 100% 7/7 slides 100% 7/7 slides Slide inventory
46 every slide · same image gating as the playbook
03
The slide highlights two distinct pipelines: TSTx (Tissue Specific Therapeutics) and NextGen CAR-T.summarize
Open slide detailBeat · Problem (Identify pain)
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.size_opportunity
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).show_traction
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).show_traction
07
Includes detailed source citations in the footer.compare_peers
08
Includes detailed source citations in the footer.show_traction
09
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
10
The slide uses a side-by-side comparison of two proprietary technology platforms.present_solution
12
The slide uses a matrix structure to compare clinical outcomes against three key value propositions.present_solution
13
Includes comparative bar charts and flow cytometry data.present_solution
14
Includes a comparison table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.argue_timing
16
The slide compares two disease indications side-by-side with clinical metrics and competitive market context.show_traction
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).compare_peers
18
The chart demonstrates deepening clinical responses over time, a key indicator of therapeutic efficacy in oncology trials.show_traction
19
The slide uses a red dashed box to highlight the key efficacy metrics for comparison.compare_peers
20
The table displays clinical trial data for NXC-201, including toxicity management metrics like Tocilizumab and Dexamethasone usage.analyze_data
21
The slide highlights specific safety data points for two dosage groups (100x10^6 and 300x10^6 cells).compare_peers
22
The slide uses a structured table-like layout to map clinical progress against specific disease indications.plan_implementation
23
The diagram illustrates a dose escalation process leading to the RP2D.plan_implementation
24
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.transition
25
Includes scientific diagrams of molecular pathways and efficacy data charts.present_solution
26
Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and pshow_traction
27
Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.show_traction
28
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.show_traction
30
Includes waterfall and spider/line charts for clinical efficacy. Source note at bottom.show_traction
31
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.compare_peers
32
The chart visualizes a single data point (4 months mPFS at 100% of patients with >=3 prior lines of therapy) as a highlighted marker.show_traction
33
Shows two parallel tracks: monotherapy and combination therapy with tislelizumab.plan_implementation
35
The slide uses a process-flow style layout to connect platform capabilities to specific drug candidates.present_solution
36
The slide uses a '3 Pillars' framework to explain the platform's foundation, leading into specific product applications.present_solution
37
Includes technical diagrams of the drug structure, bar charts for expression, and a Kaplan-Meier survival curve.present_solution
38
Includes two sets of charts: tumor volume over time and survival curves for MDA-MB-231 and HCT-116 models.show_traction
39
Includes multiple scientific diagrams and clinical trial data summaries.present_solution
41
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Selected Nexcella Scientific Advisory Board Members (bottom).other
45
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs ($33.4bn vs $0.9bn).size_opportunity
46
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-1compare_peers